Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Change in Accured Expenses (2016 - 2021)

Historic Change in Accured Expenses for Neurocrine Biosciences (NBIX) over the last 12 years, with Q4 2021 value amounting to $19.1 million.

  • Neurocrine Biosciences' Change in Accured Expenses rose 169166.67% to $19.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $56.8 million, marking a year-over-year increase of 11115.24%. This contributed to the annual value of $29.0 million for FY2024, which is 5489.89% down from last year.
  • As of Q4 2021, Neurocrine Biosciences' Change in Accured Expenses stood at $19.1 million, which was up 169166.67% from $8.7 million recorded in Q3 2021.
  • Neurocrine Biosciences' Change in Accured Expenses' 5-year high stood at $41.7 million during Q4 2019, with a 5-year trough of -$16.6 million in Q1 2019.
  • Over the past 5 years, Neurocrine Biosciences' median Change in Accured Expenses value was $10.7 million (recorded in 2017), while the average stood at $9.5 million.
  • Over the last 5 years, Neurocrine Biosciences' Change in Accured Expenses had its largest YoY gain of 352483.66% in 2017, and its largest YoY loss of 19514.27% in 2017.
  • Over the past 5 years, Neurocrine Biosciences' Change in Accured Expenses (Quarter) stood at $16.2 million in 2017, then plummeted by 46.87% to $8.6 million in 2018, then surged by 383.59% to $41.7 million in 2019, then crashed by 102.88% to -$1.2 million in 2020, then skyrocketed by 1691.67% to $19.1 million in 2021.
  • Its Change in Accured Expenses stands at $19.1 million for Q4 2021, versus $8.7 million for Q3 2021 and $18.0 million for Q2 2021.